This issue contains 7 items, and the estimated reading time is 3 minutes.

Dialysis Giant May Sell Core Business for $29 Billion

According to the Wall Street Journal, private equity giantCarlyle GroupIn collaboration with dialysis giantBaxter HealthcareConduct exclusive negotiations with the goal ofMore than 4 billion US dollars(Including Debt) PriceAcquisition of Baxter's Renal Care Subsidiary Vantive。

In 2023, Baxter Healthcare's net sales were $14.813 billion.Sales of the renal care business were $4.45 billion, accounting for up to 30% of total revenue.。

The other two companies known as the "Big Three of Dialysis"Fresenius Medical Care、DaVitaAll are making corresponding adjustments to their own kidney businesses:Either spin off independently or establish a joint venture with external partners.。

Edwards LifesciencesAnnounced, in collaboration with French medical device companyAffluent Medical AchievedTotal value of three transactions: 15 million euros (approximately 120 million RMB)The acquisition deal to obtain itsMitral Valve Technology.

Edward Life Sciences acquired the exclusive option to purchase Kephalios, a subsidiary of Affluent, for 5 million euros, including the company's production.Kalios Adjustable Mitral Annuloplasty Ring; for 5 million euros, obtainAffluent Related to Bionic Heart Mitral Valve Replacement TechnologyGlobal non-exclusive license of Intellectual Property (IP); and further investment of 5 million euros to acquire 9.21% of Affluent's shares.

Roche Obtains Certification to Enter the CGM Market

RocheAnnouncing its firstCGM (Continuous Glucose Monitoring) Products——Accu-Chek® SmartGuide CGM Solution Receives CE Mark。

This product provides 14 days of continuous real-time blood glucose monitoring for Type 1 and Type 2 diabetes patients aged 18 and above who are receiving flexible insulin therapy. Its built-in artificial intelligence training algorithm canIndicates the risk of hypoglycemia within the next 30 minutes, continuously predicts how glucose levels will develop over the next 2 hours, and estimates the risk of nocturnal hypoglycemia., which will enable users to proactively intervene before complications occur.

The European approval of the product marks Roche's official entry into the CGM market, competing with traditional giants such as Abbott and Dexcom.

Medtronic's First Overseas Global IT Center

MedtronicFirst Overseas Global IT Center (GIT)——Hyderabad Medtronic Engineering and Innovation Center (MEIC), inIndiaOfficial Inauguration in Hyderabad, Telangana.Medtronic Plans to Invest $60 Million in China Over the Next 3-5 Years, Creating 300 Jobs

The newly expanded MEIC is nowMedtronic's Largest R&D Center Outside the United States`, Focus`Cloud programs, data platforms, digital health applications, hyper-automation, and artificial intelligence/machine learningCutting-edge technologies such as...

Boston Scientific's PFA Product Approved by NMPA

July 8,Boston ScientificAnnouncement:FARAPULSE™ Series Pulsed Field Ablation Products, including FARAWAVE Single-Use Cardiac Pulsed Field Ablation Catheter, FARASTAR Cardiac Pulsed Field Ablation System,Approved by the National Medical Products Administration (NMPA)。

Thus, Boston Scientific'sFARAPULSE™ PFA SystemYesGlobally UniqueOneASimultaneously approved for marketing by the EU CE, U.S. Food and Drug Administration (FDA), and China National Medical Products Administration (NMPA).The PFA system.

Electrophysiology: Giants Compete, Domestic Products Gain Market Share

As one of the hottest tracks in the current medical device field,The leading effect in the electrophysiology track is becoming increasingly prominent., Johnson & Johnson, Medtronic, Abbott, Boston Scientific and other multinational giants continue to battle for dominance. In this process,Local companies, despite their late start, are also striving to catch up., diversifying the layout of the electrophysiology market, and advancing product development and commercialization.

Recently,Minimally Invasive ElectrophysiologyRelease of earnings forecast: expected revenue for the first half of 2024 is between 195 million yuan and 210 million yuan, representing a year-on-year increase of 37.21% to 47.76%.Net profit attributable to母公司公司 shareholders is RMB 15 million to RMB 20 million, representing a year-on-year increase of 595.92% to 827.89%.。

Another domestic electrophysiology listed company, acquired by Mindray for 6.6 billion yuanHuitai Medical, with equally impressive performance in recent years. In the first quarter of 2024, Hu Tai Medical's revenue reached 455 million yuan, a year-on-year increase of 30.20%;Net profit attributable to母公司1.40 billion yuan, a year-on-year increase of 36.48%。

According to incomplete statistics, last week (7.8-7.14) there were a total of incidents in the domestic medical device field.4 Financing Events, wherein2Early Project Financing(Pre-A round and previous rounds),1 Billion-Dollar Mega Financing Round——Critical Precision Components and Medical Device Consumables R&D, ProductionBusinessXin Zeyuan。